P53-MDM2界面的肽类及拟肽类抑制剂的研究进展  

Research progress of inhibitors of peptides and peptidomimetic acting on P53-MDM2 interface

作　　者：李翔[1] 邹燕[1] 吴茂诚[1] 黄婷[1] 胡宏岗[1] 吴秋业[1] 

机构地区：[1]第二军医大学药学院有机化学教研室,上海200433

出　　处：《药学实践杂志》2015年第6期494-497,512,共5页Journal of Pharmaceutical Practice

摘　　要：当前,肿瘤疾病以日益增高的发病率越来越受到人们的重视。抑制P53-MDM2的相互作用已经成为治疗癌症药物设计的重要靶标,通过各种药物筛选手段,研究人员发现了许多肽类及小分子抑制剂。综述近年来国内外关于肽类及拟肽类的P53-MDM2抑制剂的研究进展。Tumor diseases have attracted great attention of the society because of the increasing morbidity in recent years .To inhibit the P53-MDM2 interaction has become an important target for design of cancer drug ,and a lot of peptide and small molecule inhibitors have been found with various kinds of drug screening and research tools .This paper summarized the recent progress of the peptide and peptidomimetic inhibitors of P53-MDM2 at home and abroad lately .

关 键 词：P53-MDM2 肽 抑制剂 

分 类 号：R73-3[医药卫生—肿瘤] Q51[医药卫生—临床医学]